Representative CEUS images with BR55 of mice with a subcutaneous tumour allograft (arrows) under treatment. حسب Felix L. Herr (21544362)

The mean and standard deviation of parameters. حسب Sadaf Sepasgozar Sarkhosh (20436143)

"…Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …"

The ANCOVA and Post_hoc results. حسب Sadaf Sepasgozar Sarkhosh (20436143)

"…Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …"

CONSORT flowchart. حسب Sadaf Sepasgozar Sarkhosh (20436143)

"…Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …"

Time to stabilization in the vertical direction. حسب Sadaf Sepasgozar Sarkhosh (20436143)

"…Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …"

The description of games. حسب Sadaf Sepasgozar Sarkhosh (20436143)

"…Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …"

The description of balance training. حسب Sadaf Sepasgozar Sarkhosh (20436143)

"…Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …"

Participant demographic and clinical characteristics. حسب Claire M. Douglas (21238238)

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. حسب Claire M. Douglas (21238238)

Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... حسب Claire M. Douglas (21238238)

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... حسب Claire M. Douglas (21238238)

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 2 times/week) or did not meet (< 2 times/week) WHO’s resistance traini... حسب Claire M. Douglas (21238238)

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  حسب Claire M. Douglas (21238238)

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  حسب Claire M. Douglas (21238238)

Comparison of data after the experiment. حسب Neng Pan (5262032)

Baseline characteristics. حسب Neng Pan (5262032)

"…Following the intervention, the HIIT NW group exhibited a marked increase in limb lean mass, which led to a significant rise in the skeletal muscle index (SMI) (p < 0.001). …"

Data ste. حسب Neng Pan (5262032)

"…Following the intervention, the HIIT NW group exhibited a marked increase in limb lean mass, which led to a significant rise in the skeletal muscle index (SMI) (p < 0.001). …"

Comparison of post-experimental outcome measures. حسب Neng Pan (5262032)

"…Following the intervention, the HIIT NW group exhibited a marked increase in limb lean mass, which led to a significant rise in the skeletal muscle index (SMI) (p < 0.001). …"

5-HT supplementation induces mitochondrial damage. حسب Li Gao (131516)

Brain disintegration in <i>aP2- Drp1</i>^f/f neonatal mice. حسب Yuta Ibayashi (20404811)